{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:59:09Z","timestamp":1791568749958,"version":"4.3.4"},"reference-count":122,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2021,7,3]]},"DOI":"10.1080\/14728214.2021.1952982","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T18:16:18Z","timestamp":1625595378000},"page":"259-270","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":21,"title":["Emerging drugs for the treatment of myasthenia gravis"],"prefix":"10.1080","volume":"26","author":[{"given":"Deepak","family":"Menon","sequence":"first","affiliation":[{"name":"Department of Medicine, Ellen & Martin Prosserman Centre for Neuromuscular Diseases, University Health Network, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Urra Pincheira","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ellen & Martin Prosserman Centre for Neuromuscular Diseases, University Health Network, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Bril","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ellen & Martin Prosserman Centre for Neuromuscular Diseases, University Health Network, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1586\/eci.12.34"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-10-46"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181a41211"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013278"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-129"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-829584"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000256698.69121.45"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31821e5505"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14547"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602489"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneuro0810"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23626"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.3233\/JND-140045"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2015.10.009"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1159\/000279334"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000858"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.80a.13044"},{"key":"cit0018","unstructured":"Myasthenia Gravis Treatment Market Size, Share | Industry Report, 2026 [Internet]. [cited 2021 May 13]. Available from: https:\/\/www.grandviewresearch.com\/industry-analysis=\/myasthenia-gravis-mg-treatment-market\/toc?__hstc=753710.c9f347df1097a18f747a00e987e76357.1620896958861.1620896958861.1620896958861.1&__hssc=753710.1.1620896958861&__hsfp=454551083"},{"key":"cit0019","unstructured":"Ltd R and M. Myasthenia Gravis Treatment - Global Market Trajectory & Analytics [Internet]. [cited 2021 May 29]. Available from: https:\/\/www.researchandmarkets.com\/reports\/5303676\/myasthenia-gravis-treatment-global-market"},{"key":"cit0020","unstructured":"Markets R and. Global Myasthenia Gravis Drugs Industry (2020 to 2027). Market trajectory & analytics [internet]. GlobeNewswire News Room. 2021. [cited 2021 May 29]. Available from: https:\/\/www.globenewswire.com\/news-release\/2021\/04\/07\/2205763\/28124\/en\/Global-Myasthenia-Gravis-Drugs-Industry-2020-to-2027-Market-Trajectory-Analytics.html"},{"key":"cit0021","unstructured":"Global myasthenia gravis epidemiology forecast to 2028 - researchAndMarkets.com [Internet]. 2019. [cited 2021 May 13]. Available from: https:\/\/www.businesswire.com\/news\/home\/20191031005683\/en\/Global-Myasthenia-Gravis-Epidemiology-Forecast-to-2028-ResearchAndMarkets.com"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.011"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1573-2"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617749134"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14675"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00538"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13522"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1344"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1515\/revneuro-2014-0021"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1405.009"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.5.12.1916092"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03052"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.8.5390"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25973"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00835"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.2174\/1389201019666180418095526"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00742-8"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23839"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1"},{"issue":"1","key":"cit0041","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","volume":"60","author":"Muppidi S","journal-title":"Muscle Nerve"},{"issue":"0","key":"cit0042","first-page":"1","volume":"0","author":"Jr JFH","journal-title":"Expert Opin Investig Drugs"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00401-1"},{"issue":"5","key":"cit0044","first-page":"1","volume":"77","author":"Howard JF","journal-title":"JAMA Neurol"},{"key":"cit0045","unstructured":"Zilucoplan gets orphan designation in myasthenia gravis ahead of phase 3 trial [internet]. Neurology live. [cited 2021 May 22]. Available from: https:\/\/www.neurologylive.com\/view\/zilucoplan-get-orphan-designation-myasthenia-gravis-ahead-phase-3-trial"},{"key":"cit0046","unstructured":"Safety, tolerability, and efficacy of Zilucoplan in subjects with generalized myasthenia gravis - full text view - clinicalTrials.gov [internet]. [cited 2020 Mar 21]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04115293"},{"key":"cit0047","author":"Sheridan D","journal-title":"PLoS One"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719874728"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876805"},{"key":"cit0050","unstructured":"Alexion Pharmaceuticals. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Na\u00efve Adult Patients With Generalized Myasthenia Gravis [Internet]. clinicaltrials.gov, 2020 Dec [cited 2021 May 20]. Report No.: NCT03920293. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03920293"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03052"},{"key":"cit0052","author":"Ulrichts P","journal-title":"J Clin Invest."},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2016.1214823"},{"key":"cit0054","unstructured":"argenx. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness [Internet]. clinicaltrials.gov, 2021 Mar [cited 2021 May 27]. Report No.: NCT03669588. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03669588"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1276"},{"key":"cit0057","unstructured":"Momenta Pharmaceuticals, Inc. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis [Internet]. clinicaltrials.gov, 2021 Mar [cited 2021 May 27]. Report No.: NCT03772587. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03772587"},{"key":"cit0058","unstructured":"PhD SB Rapid and durable response to nipocalimab in gMG, phase 2 trial shows [internet]. [cited 2021 May 30]. Available from: https:\/\/myastheniagravisnews.com\/news-posts\/2020\/06\/16\/rapid-and-durable-response-to-nipocalimab-in-gmg-phase-2-trial-shows\/"},{"key":"cit0059","unstructured":"A study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of M281 administered to pregnant women at high risk for early onset severe hemolytic disease of the fetus and newborn (HDFN) - full text view. ClinicalTrials.gov [Internet]. [cited 2020 Mar 22]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03842189"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan1208"},{"issue":"6","key":"cit0061","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","volume":"96","author":"Bril V","journal-title":"Neurology"},{"key":"cit0062","unstructured":"Pinto D. Phase 2 study shows Rozanolixizumab is safe and effective in \u2026 [internet]. Myasthenia Gravis News. 2018. [cited 2020 Apr 3]. Available from: https:\/\/myastheniagravisnews.com\/2018\/10\/23\/phase-2-study-shows-rozanolixizumab-safe-effective-alleviating-mg-symptoms\/"},{"key":"cit0063","unstructured":"A study to test efficacy and safety of Rozanolixizumab in adult patients with generalized myasthenia gravis - full text view. ClinicalTrials.gov [Internet]. [cited 2020 Mar 22]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03971422"},{"key":"cit0064","doi-asserted-by":"crossref","unstructured":"Collins J, Jones LS, Snyder M, et al. RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration (P5.2-079). In 2019.","DOI":"10.1212\/WNL.92.15_supplement.P5.2-079"},{"key":"cit0065","unstructured":"A study of RVT-1401 in myasthenia gravis (MG) patients - full text view. ClinicalTrials.gov [Internet]. [cited 2020 Apr 3]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03863080"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206939"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.011"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00613"},{"key":"cit0070","unstructured":"Yale University. B Cell Targeted Treatment In Myasthenia Gravis (BeatMG): A Phase II Trial of Rituximab In Myasthenia Gravis [Internet]. clinicaltrials.gov, 2020 Mar [cited 2021 May 20]. Report No.: NCT02110706. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02110706"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26790"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.0851"},{"issue":"3","key":"cit0074","volume":"24","author":"Berger JR","year":"2018","journal-title":"J NeuroVirology"},{"key":"cit0075","author":"Du FH","journal-title":"Auto-Immun Highlights"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.21338"},{"key":"cit0077","author":"Waters MJ","journal-title":"Muscle Nerve"},{"key":"cit0078","author":"Chen D","journal-title":"J Clin Med. Nov 24;5(12):107"},{"key":"cit0079","author":"Frampton JE","journal-title":"Drugs"},{"key":"cit0080","unstructured":"Viela B. A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study With Open-label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults With Myasthenia Gravis [Internet]. clinicaltrials.gov, 2021 Mar [cited 2021 May 24]. Report No.: NCT04524273. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04524273"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8539"},{"key":"cit0082","unstructured":"Takeda. A phase 2, randomized, placebo-controlled study to evaluate safety, tolerability, and efficacy of TAK-079 in patients with generalized myasthenia gravis [internet]. clinicaltrials.gov, 2021 Mar [cited 2021 May 27]. Report No.: NCT04159805. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04159805"},{"key":"cit0083","author":"Alabbad S","journal-title":"Biodrugs"},{"key":"cit0084","unstructured":"Novartis Pharmaceuticals. A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Preliminarily Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of CFZ533 in Patients With Moderate to Severe Myasthenia Gravis [Internet]. clinicaltrials.gov, 2020 Dec [cited 2021 May 27]. Report No.: results\/NCT02565576. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02565576"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.11.1697"},{"key":"cit0086","unstructured":"B-cell-activating factor and autoimmune myasthenia gravis [internet]. [cited 2020 Mar 22]. Available from: https:\/\/www.hindawi.com\/journals\/ad\/2011\/939520\/"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25162"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005323"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1065-0"},{"key":"cit0090","first-page":"e5727516","volume":"2019","author":"Chen Y","journal-title":"J Immunol Res"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-017-0102-y"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0042-2"},{"key":"cit0093","first-page":"1","volume":"2019","author":"Chen Y","journal-title":"J Immunol Res"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.11"},{"key":"cit0095","unstructured":"Cartesian Therapeutics. Autologous T-Cells Expressing A Chimeric Antigen Receptor Directed To B-Cell Maturation Antigen (BCMA) In Patients With Generalized Myasthenia Gravis (MG) [Internet]. clinicaltrials.gov, 2021 Feb [cited 2021 May 20]. Report No.: NCT04146051. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04146051"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138416"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100645"},{"issue":"15","key":"cit0098","volume":"94","author":"Oh S","journal-title":"Neurology"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.251"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000531"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3290894"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316271"},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.0113"},{"key":"cit0105","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.7"},{"key":"cit0106","unstructured":"Autologous peripheral blood stem cell transplant for neurologic autoimmune diseases - full text view. ClinicalTrials.gov [Internet]. [cited 2020 Mar 25]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00716066"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00461"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2020.06.011"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.596382"},{"key":"cit0110","author":"Dougados M","journal-title":"Lancet Rheumatol"},{"key":"cit0111","unstructured":"Research C for DE and. FDA guidance on conduct of clinical trials of medical products during the COVID-19 public health emergency [internet]. U.S. Food and Drug Administration. FDA, 2021. [cited 2021 May 26]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-public-health-emergency"},{"key":"cit0112","unstructured":"Updated guidance on the management of clinical trials during COVID-19 - ECA academy [internet]. [cited 2021 May 26]. Available from: https:\/\/www.gmp-compliance.org\/gmp-news\/updated-guidance-on-the-management-of-clinical-trials-during-cov19"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.14195"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2014.12.022"},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00212"},{"key":"cit0116","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.12.003"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007605"},{"key":"cit0118","unstructured":"Information NC for B, Pike USNL of M 8600 R, MD B, Usa 20894. Cost comparison table [internet]. Pharmacoeconomic Report: Eculizumab (Soliris): Alexion Pharma Canada Corp. Indication: Neuromyelitis optica spectrum disorder [Internet]. Canadian Agency for Drugs and Technologies in Health, 2020. [cited 2021 May 28]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK567499\/"},{"issue":"6","key":"cit0119","first-page":"1","volume":"10","author":"Vincent Rajkumar S","journal-title":"Blood Cancer J"},{"key":"cit0120","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-42"},{"issue":"7","key":"cit0121","first-page":"22","volume":"33","author":"Khedraki R","journal-title":"Fed Pract"},{"issue":"1","key":"cit0122","volume":"1413","author":"Jt G","journal-title":"Ann N Y Acad Sci"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2021.1952982","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T13:29:38Z","timestamp":1725370178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2021.1952982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,3]]},"references-count":122,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7,3]]}},"alternative-id":["10.1080\/14728214.2021.1952982"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2021.1952982","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-06-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}